TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Brief Summary: The purpose of this study is to determine whether ozanimod is effective in the treatment of relapsing multiple sclerosis (RMS).


Options:
A: Arm Label: Group 1; Type: EXPERIMENTAL; Interventions: Drug: Natalizumab | Arm Label: Group 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Natalizumab; Assigned to Arm(s): Group 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Group 2
B: Arm Label: Fingolimod (FTY720); Type: EXPERIMENTAL; Interventions: Drug: Fingolimod | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Comparator | Intervention Type: DRUG; Name: Fingolimod; Assigned to Arm(s): Fingolimod (FTY720) | Intervention Type: DRUG; Name: Placebo Comparator; Assigned to Arm(s): Placebo
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 150 mg DAC HYP; Type: EXPERIMENTAL; Interventions: Biological: BIIB019 (Daclizumab High Yield Process) | Arm Label: 300 mg DAC HYP; Type: EXPERIMENTAL; Interventions: Biological: BIIB019 (Daclizumab High Yield Process) | Intervention Type: BIOLOGICAL; Name: BIIB019 (Daclizumab High Yield Process); Assigned to Arm(s): 150 mg DAC HYP, 300 mg DAC HYP | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Interferon beta-1a; Type: ACTIVE_COMPARATOR; Interventions: Drug: Interferon beta-1a, Drug: Placebo to ozanimod | Arm Label: Ozanimod 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: Ozanimod, Drug: Placebo to interferon beta-1a | Arm Label: Ozanimod 1 mg; Type: EXPERIMENTAL; Interventions: Drug: Ozanimod, Drug: Placebo to interferon beta-1a | Intervention Type: DRUG; Name: Ozanimod; Assigned to Arm(s): Ozanimod 0.5 mg, Ozanimod 1 mg | Intervention Type: DRUG; Name: Interferon beta-1a; Assigned to Arm(s): Interferon beta-1a | Intervention Type: DRUG; Name: Placebo to ozanimod; Assigned to Arm(s): Interferon beta-1a | Intervention Type: DRUG; Name: Placebo to interferon beta-1a; Assigned to Arm(s): Ozanimod 0.5 mg, Ozanimod 1 mg

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter Randomized Trial Evaluating the Efficacy of Sarpogrelate on Ischemic Heart Disease After Drug-eluting Stent Implantation in Patients With Diabetes Mellitus or Renal Impairment
Brief Summary: The purpose of the SERENADE trial is to evaluate the safety and efficacy of sarpogrelate in patients with CKD or DM after DES implantation.


Options:
A: Arm Label: aspirin, clopidogrel & sarpogrelate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sarpogrelate, Drug: Aspirin, Drug: Clopidogrel | Arm Label: aspirin, clopidogrel & placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Aspirin, Drug: Clopidogrel, Drug: Placebo (for Sarpogrelate) | Intervention Type: DRUG; Name: Sarpogrelate; Assigned to Arm(s): aspirin, clopidogrel & sarpogrelate | Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): aspirin, clopidogrel & placebo, aspirin, clopidogrel & sarpogrelate | Intervention Type: DRUG; Name: Clopidogrel; Assigned to Arm(s): aspirin, clopidogrel & placebo, aspirin, clopidogrel & sarpogrelate | Intervention Type: DRUG; Name: Placebo (for Sarpogrelate); Assigned to Arm(s): aspirin, clopidogrel & placebo
B: Arm Label: Active Clonidine and Active ASA; Type: EXPERIMENTAL; Interventions: Drug: Active Clonidine, Drug: Active ASA | Arm Label: Active Clonidine and Placebo ASA; Type: EXPERIMENTAL; Interventions: Drug: Active Clonidine, Drug: Placebo ASA | Arm Label: Placebo Clonidine and Active ASA; Type: EXPERIMENTAL; Interventions: Drug: Placebo Clonidine, Drug: Active ASA | Arm Label: Placebo Clonidine and Placebo ASA; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Clonidine, Drug: Placebo ASA | Intervention Type: DRUG; Name: Active Clonidine; Assigned to Arm(s): Active Clonidine and Active ASA, Active Clonidine and Placebo ASA | Intervention Type: DRUG; Name: Placebo Clonidine; Assigned to Arm(s): Placebo Clonidine and Active ASA, Placebo Clonidine and Placebo ASA | Intervention Type: DRUG; Name: Active ASA; Assigned to Arm(s): Active Clonidine and Active ASA, Placebo Clonidine and Active ASA | Intervention Type: DRUG; Name: Placebo ASA; Assigned to Arm(s): Active Clonidine and Placebo ASA, Placebo Clonidine and Placebo ASA
C: Arm Label: aspirin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aspirin | Arm Label: standard medication; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): aspirin
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Ticagrelor 90 mg | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Ticagrelor 60 mg | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Ticagrelor Placebo | Intervention Type: DRUG; Name: Ticagrelor 90 mg; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Ticagrelor 60 mg; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Ticagrelor Placebo; Assigned to Arm(s): 3

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Family Startup Program. A Randomized Controlled Trial of a Universal Group-based Parenting Support Program
Brief Summary: The aims of this study are to determine whether a group-based parent support program ("Family Startup") can lead to early improved parental sense of competence, family relations, and child development. Evaluation is based on a randomized controlled trial, with half of the participants receiving Family Startup and the other half receiving treatment as usual.


Options:
A: Arm Label: Family Startup; Type: EXPERIMENTAL; Interventions: Other: Family Startup (in Danish: Familieiværksætterne) | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Family Startup (in Danish: Familieiværksætterne); Assigned to Arm(s): Family Startup
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Parenting group | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Parenting group; Assigned to Arm(s): 1
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Incredible Years Program | Arm Label: 2; Type: OTHER; Interventions: Behavioral: Incredible Years Program | Intervention Type: BEHAVIORAL; Name: Incredible Years Program; Assigned to Arm(s): 1, 2
D: Arm Label: Intervention Chicago Parent Program arm; Type: EXPERIMENTAL; Interventions: Behavioral: Chicago Parent Program | Arm Label: Parent-Child Interaction Therapy; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Parent-Child Interaction Therapy | Intervention Type: BEHAVIORAL; Name: Chicago Parent Program; Assigned to Arm(s): Intervention Chicago Parent Program arm | Intervention Type: BEHAVIORAL; Name: Parent-Child Interaction Therapy; Assigned to Arm(s): Parent-Child Interaction Therapy

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: ActiveBrains: Effects of an Exercise-based Randomized Controlled Trial on Cognition, Brain Structure and Brain Function in Overweight/Obese Preadolescent Children
Brief Summary: The ActiveBrains project aims to examine whether a 5-months physical exercise program has benefits on cognition and brain, as well as on selected physical and mental health outcomes in preadolescent overweight/obese children.


Options:
A: Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention Group; Type: EXPERIMENTAL; Interventions: Behavioral: A 5-months physical exercise-based program | Intervention Type: BEHAVIORAL; Name: A 5-months physical exercise-based program; Assigned to Arm(s): Intervention Group
B: Arm Label: A+PAAC; Type: EXPERIMENTAL; Interventions: Behavioral: A+PAAC | Arm Label: CON; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: CON | Intervention Type: BEHAVIORAL; Name: A+PAAC; Assigned to Arm(s): A+PAAC | Intervention Type: BEHAVIORAL; Name: CON; Assigned to Arm(s): CON
C: Arm Label: Intervention camp; Type: EXPERIMENTAL; Interventions: Behavioral: Intervention camp | Arm Label: Small intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Small intervention | Intervention Type: BEHAVIORAL; Name: Small intervention; Assigned to Arm(s): Small intervention | Intervention Type: BEHAVIORAL; Name: Intervention camp; Assigned to Arm(s): Intervention camp
D: Intervention Type: BEHAVIORAL; Name: diet, reducing; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: ActiveBrains: Effects of an Exercise-based Randomized Controlled Trial on Cognition, Brain Structure and Brain Function in Overweight/Obese Preadolescent Children
Brief Summary: The ActiveBrains project aims to examine whether a 5-months physical exercise program has benefits on cognition and brain, as well as on selected physical and mental health outcomes in preadolescent overweight/obese children.


Options:
A: Arm Label: NewNordicDiet first; Type: OTHER; Interventions: Other: School meals based on the principles of the New Nordic Diet | Arm Label: NewNordicDiet last; Type: OTHER; Interventions: Other: School meals based on the principles of the New Nordic Diet | Intervention Type: OTHER; Name: School meals based on the principles of the New Nordic Diet; Assigned to Arm(s): NewNordicDiet first, NewNordicDiet last
B: Arm Label: A+PAAC; Type: EXPERIMENTAL; Interventions: Behavioral: A+PAAC | Arm Label: CON; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: CON | Intervention Type: BEHAVIORAL; Name: A+PAAC; Assigned to Arm(s): A+PAAC | Intervention Type: BEHAVIORAL; Name: CON; Assigned to Arm(s): CON
C: Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention Group; Type: EXPERIMENTAL; Interventions: Behavioral: A 5-months physical exercise-based program | Intervention Type: BEHAVIORAL; Name: A 5-months physical exercise-based program; Assigned to Arm(s): Intervention Group
D: Arm Label: COPE/Healthy Lifestyles TEEN Program; Type: EXPERIMENTAL; Interventions: Behavioral: COPE/Healthy Lifestyles TEEN Program. | Arm Label: Healthy Teens Attention Control Program; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Healthy Teens Attention Control Program | Intervention Type: BEHAVIORAL; Name: COPE/Healthy Lifestyles TEEN Program.; Assigned to Arm(s): COPE/Healthy Lifestyles TEEN Program | Intervention Type: BEHAVIORAL; Name: Healthy Teens Attention Control Program; Assigned to Arm(s): Healthy Teens Attention Control Program

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Controlled Parallel-group Trial to Investigate the Effectiveness of Two Silicone Dressings for Sacral and Heel Pressure Ulcer Prevention Compared to no Dressings
Brief Summary: The aim of this randomized controlled trial is to test the efficacy of preventive dressings for pressure ulcer prevention.


Options:
A: Arm Label: skin care arm of where evidence-based practices in the implementation guide; Type: EXPERIMENTAL; Interventions: Other: skin care arm of where evidence-based practices in the implementation guide | Arm Label: hydrocolloid (Convatec Granuflex-extra thin) dressing; Type: EXPERIMENTAL; Interventions: Device: hydrocolloid (Convatec Granuflex-extra thin) dressing | Arm Label: control; Type: OTHER; Interventions: Other: control | Intervention Type: OTHER; Name: skin care arm of where evidence-based practices in the implementation guide; Assigned to Arm(s): skin care arm of where evidence-based practices in the implementation guide | Intervention Type: DEVICE; Name: hydrocolloid (Convatec Granuflex-extra thin) dressing; Assigned to Arm(s): hydrocolloid (Convatec Granuflex-extra thin) dressing | Intervention Type: OTHER; Name: control; Assigned to Arm(s): control
B: Arm Label: Mepilex® Border; Type: EXPERIMENTAL; Interventions: Device: Mepilex® Border Sacrum and Mepilex® Border Heel | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Mepilex® Border Sacrum and Mepilex® Border Heel; Assigned to Arm(s): Mepilex® Border
C: Arm Label: Hyper-oxigenated fatty acid; Type: ACTIVE_COMPARATOR; Interventions: Drug: Hyper-oxigenated fatty acid | Arm Label: Olive oil's Cream; Type: EXPERIMENTAL; Interventions: Other: Olive oil's cream | Intervention Type: DRUG; Name: Hyper-oxigenated fatty acid; Assigned to Arm(s): Hyper-oxigenated fatty acid | Intervention Type: OTHER; Name: Olive oil's cream; Assigned to Arm(s): Olive oil's Cream
D: Arm Label: Hydrocellular polyurethane foam multilayer dressing; Type: EXPERIMENTAL; Interventions: Device: Hydrocellular polyurethane foam multilayer dressing, Procedure: Standard preventive care | Arm Label: standard preventive care; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Standard preventive care | Intervention Type: DEVICE; Name: Hydrocellular polyurethane foam multilayer dressing; Assigned to Arm(s): Hydrocellular polyurethane foam multilayer dressing | Intervention Type: PROCEDURE; Name: Standard preventive care; Assigned to Arm(s): Hydrocellular polyurethane foam multilayer dressing, standard preventive care

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Double-blind, Randomised Study to Assess the Safety and Efficacy of AZD9291 Versus a Standard of Care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as First Line Treatment in Patients With Epidermal Growth Factor Receptor Mutation Positive, Locally Advanced or Metastatic Non Small Cell Lung Cancer.
Brief Summary: To assess the efficacy and safety of AZD9291 versus a standard of care epidermal growth factor receptor tyrosine kinase inhibitor in patients with locally advanced or Metastatic Non Small Cell Lung Cancer


Options:
A: Intervention Type: DRUG; Name: Gefitinib; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Vinorelbine; Assigned to Arm(s): N/A
B: Arm Label: Icotinib; Type: EXPERIMENTAL; Interventions: Drug: Icotinib | Arm Label: Chemotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Chemotherapy | Intervention Type: DRUG; Name: Icotinib; Assigned to Arm(s): Icotinib | Intervention Type: DRUG; Name: Chemotherapy; Assigned to Arm(s): Chemotherapy
C: Arm Label: AZD9291+ placebo; Type: EXPERIMENTAL; Interventions: Drug: AZD9291 80 mg/40 mg + placebo, Drug: Placebo Erlotinib 150/100mg, Drug: Placebo Gefitinib 250 mg | Arm Label: Standard of Care + placebo AZD9291; Type: ACTIVE_COMPARATOR; Interventions: Drug: Erlotinib 150/100 mg, Drug: Gefitinib 250 mg, Drug: Placebo AZD9291 80 mg/ 40 mg | Intervention Type: DRUG; Name: AZD9291 80 mg/40 mg + placebo; Assigned to Arm(s): AZD9291+ placebo | Intervention Type: DRUG; Name: Placebo Erlotinib 150/100mg; Assigned to Arm(s): AZD9291+ placebo | Intervention Type: DRUG; Name: Placebo Gefitinib 250 mg; Assigned to Arm(s): AZD9291+ placebo | Intervention Type: DRUG; Name: Erlotinib 150/100 mg; Assigned to Arm(s): Standard of Care + placebo AZD9291 | Intervention Type: DRUG; Name: Gefitinib 250 mg; Assigned to Arm(s): Standard of Care + placebo AZD9291 | Intervention Type: DRUG; Name: Placebo AZD9291 80 mg/ 40 mg; Assigned to Arm(s): Standard of Care + placebo AZD9291
D: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Erlotinib | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carboplatin, Drug: Gemcitabin, Drug: Docetaxel, Drug: Cisplatin | Intervention Type: DRUG; Name: Erlotinib; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Gemcitabin; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Docetaxel; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): B

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effective Surveillance and Impact of HPV Vaccination on Screening for Cervical Cancer in Tuscany
Brief Summary: The purposes of this study are to evaluate the effectiveness of vaccination in 25-year old women at the time of their first access to cervical cancer screening, to understand the impact of vaccination on screening activity; to evaluate the immune response following vaccination; to study the dynamics of the infection after vaccination, including the possible change in the frequency of non-vaccine HPV types, to evaluate cytological abnormalities reductions in vaccinated women and to assess if HPV test in urine sample could be a useful non-invasive method to monitor HPV status in younger women.


Options:
A: N/A
B: Arm Label: no HPV vaccine; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: HPV vaccine (Cervarix®, GlaxoSmithKline); Type: EXPERIMENTAL; Interventions: Biological: Cervarix®, GlaxoSmithKline | Intervention Type: BIOLOGICAL; Name: Cervarix®, GlaxoSmithKline; Assigned to Arm(s): HPV vaccine (Cervarix®, GlaxoSmithKline)
C: Arm Label: Cervarix 1/Placebo Group; Type: EXPERIMENTAL; Interventions: Biological: Cervarix, Drug: Placebo | Arm Label: Cervarix 1/Placebo/Cervarix 1 Group; Type: EXPERIMENTAL; Interventions: Biological: Cervarix, Drug: Placebo | Arm Label: Cervarix 2/Placebo/Cervarix 2 Group; Type: EXPERIMENTAL; Interventions: Biological: Cervarix, Drug: Placebo | Arm Label: Cervarix 2 Group; Type: EXPERIMENTAL; Interventions: Biological: Cervarix | Intervention Type: BIOLOGICAL; Name: Cervarix; Assigned to Arm(s): Cervarix 1/Placebo Group, Cervarix 1/Placebo/Cervarix 1 Group, Cervarix 2 Group, Cervarix 2/Placebo/Cervarix 2 Group | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cervarix 1/Placebo Group, Cervarix 1/Placebo/Cervarix 1 Group, Cervarix 2/Placebo/Cervarix 2 Group
D: Arm Label: 0,2,6 month vaccination schedule; Type: ACTIVE_COMPARATOR; Interventions: Biological: Biological: quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine | Arm Label: 0,3,9 month vaccination schedule; Type: ACTIVE_COMPARATOR; Interventions: Biological: Biological: quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine | Arm Label: 0,6,12 month vaccination schedule; Type: ACTIVE_COMPARATOR; Interventions: Biological: Biological: quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine | Arm Label: 0,12,24 month vaccination schedule; Type: ACTIVE_COMPARATOR; Interventions: Biological: Biological: quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine | Intervention Type: BIOLOGICAL; Name: Biological: quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine; Assigned to Arm(s): 0,12,24 month vaccination schedule, 0,2,6 month vaccination schedule, 0,3,9 month vaccination schedule, 0,6,12 month vaccination schedule

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The C-MAC Videolaryngoscope Compared With Conventional Laryngoscopy for Rapid Sequence Intubation at the Emergency Department
Brief Summary: All patients undergoing emergent endotracheal intubation (RSI) at the Emergency Department will be screened for inclusion in this clinical study. The indication of endotracheal intubation is an exclusively clinical decision and is not affected by this study protocol in any aspect.

If fulfilling the In- and exclusion criteria's, patient will be randomly assigned to one of two groups

1. C-MAC Videolaryngoscope in appropriate size
2. conventional endotracheal intubation using Macintosh Blade in appropriate size

Randomization (1:1) will be based on computer-generated codes maintained in sequentially numbered opaque envelopes that will be opened immediately before randomization.


Options:
A: Arm Label: McGrath MAC; Type: EXPERIMENTAL; Interventions: Device: the McGrath MAC | Arm Label: Macintosh Laryngoscope; Type: EXPERIMENTAL; Interventions: Device: the Macintosh Laryngoscope | Intervention Type: DEVICE; Name: the McGrath MAC; Assigned to Arm(s): McGrath MAC | Intervention Type: DEVICE; Name: the Macintosh Laryngoscope; Assigned to Arm(s): Macintosh Laryngoscope
B: Arm Label: McGrath videolaryngoscopy; Type: EXPERIMENTAL; Interventions: Device: McGrath videolaryngoscopy | Arm Label: Direct laryngoscopy; Type: ACTIVE_COMPARATOR; Interventions: Device: Direct laryngoscopy | Intervention Type: DEVICE; Name: McGrath videolaryngoscopy; Assigned to Arm(s): McGrath videolaryngoscopy | Intervention Type: DEVICE; Name: Direct laryngoscopy; Assigned to Arm(s): Direct laryngoscopy
C: Arm Label: conventional endotracheal intubation; Type: ACTIVE_COMPARATOR; Interventions: Device: Macintosh blade | Arm Label: C-MAC; Type: ACTIVE_COMPARATOR; Interventions: Device: C-MAC videolaryngoscope | Intervention Type: DEVICE; Name: Macintosh blade; Assigned to Arm(s): conventional endotracheal intubation | Intervention Type: DEVICE; Name: C-MAC videolaryngoscope; Assigned to Arm(s): C-MAC
D: Arm Label: Videolaryngoscope McGrath Mac; Type: ACTIVE_COMPARATOR; Interventions: Device: Videolaryngoscope | Arm Label: Standard laryngoscope; Type: PLACEBO_COMPARATOR; Interventions: Device: Standard laryngoscope | Intervention Type: DEVICE; Name: Videolaryngoscope; Assigned to Arm(s): Videolaryngoscope McGrath Mac | Intervention Type: DEVICE; Name: Standard laryngoscope; Assigned to Arm(s): Standard laryngoscope

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Prospective Multicenter Cohort Study to Evaluate the Benefit of the Geriatric Fracture Center (GFC) Concept
Brief Summary: The study will assess patients with at least one major AE related to treatment / hospitalization / immobilization in the Geriatric Fracture Center (GFC) group compared to the usual care group.


Options:
A: Arm Label: Care pathway teams.; Type: EXPERIMENTAL; Interventions: Behavioral: Care pathway. | Arm Label: Usual care teams.; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Care pathway.; Assigned to Arm(s): Care pathway teams.
B: Arm Label: GFC: Geriatric Fracture Center; Type: N/A; Interventions: N/A | Arm Label: UCC: Usual Care Center; Type: N/A; Interventions: N/A
C: Arm Label: Enhanced acute medical rehabilitation; Type: EXPERIMENTAL; Interventions: Behavioral: Enhanced acute medical rehabilitation | Arm Label: Treatment as usual; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Treatment as usual | Intervention Type: BEHAVIORAL; Name: Enhanced acute medical rehabilitation; Assigned to Arm(s): Enhanced acute medical rehabilitation | Intervention Type: BEHAVIORAL; Name: Treatment as usual; Assigned to Arm(s): Treatment as usual
D: Arm Label: Pathway; Type: EXPERIMENTAL; Interventions: Other: PFF evidence based pathway | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: PFF evidence based pathway; Assigned to Arm(s): Pathway

Answer: B